Shares in Senseonics (NYSE:SENS) have fallen slightly today after the continuous glucose monitoring-focused medtech company posted first quarter earnings that missed on earnings per share expectations but beat sales consensus on Wall Street. The Germantown, Md.-based company posted losses of $22.3 million, or 16¢ per share, on sales of $2.9 million for the three months […]
Senseonics
FDA committee backs Senseonics’ implantable continuous glucose monitor
An FDA advisory panel voted unanimously to recommend approval for Senseonics‘ (NYSE:SENS) implantable continuous glucose monitor, Eversense, the company touted this week. The panel of medical experts voted 8-0 that the benefits of the technology outweigh the risks and that the system, which works for up to 90 days, is safe and effective. The company’s […]
Senseonics tops Q4 EPS estimates, misses sales expectations
Shares in Senseonics (NYSE:SENS) closed down -3% yesterday after the medical device maker met earnings expectations on Wall Street with its fourth quarter and full-year financial results, but narrowly missed sales estimates. The Germantown, Md.-based company posted a net loss of -$16.3 million, or -12¢ per share, on sales of $2.9 million for the 3 months ended […]
FDA panel to review Senseonics’ implantable CGM this month
A panel for the FDA is slated to review Senseonics‘ (NYSE:SENS) premarket approval application for its Eversense implantable continuous glucose monitoring system on March 29. The company’s device sends glucose data every five minutes to a transmitter, which then communicates that information to a mobile app, displaying the values in the real-time. The Eversense system […]
Senseonics’ implantable glucose monitor succeeds in 90-day trial
A 90-day trial involving patients with Type I and Type II diabetes showed that Senseonics‘ (NYSE:SENS) implantable continuous glucose monitor was safe and accurate compared to reference glucose values, according to a study published in Diabetes Technology & Therapeutics. The single-arm study enrolled 90 participants and implanted them with Senseonics’ Eversense device, which sends glucose data […]
Senseonics prices $50m notes offering, touts Q4 and full-year prelims
Senseonics (NYSE:SENS) announced today an underwritten offering of $50 million in 5.25% convertible senior notes due 2023, alongside a 30-day option for underwriters to buy up to an additional $7.5 million in notes to cover over-allotments. The notes, which mature on Feb. 1, 2023, will be convertible into shares of Senseonics’ common stock at approximately $3.40 […]
Senseonics tops sales estimates with Q3 results
Shares in Senseonics (NYSE:SENS) fell today even though the medical technology company beat expectations on Wall Street with its third quarter results. The Germantown, Md.-based company posted a loss of -$17.4 million on sales of $2.1 million for the 3 months ended Sept. 30. Adjusted to exclude 1-time items, earnings per share were -13¢, in-line […]
Senseonics wins CE Mark for Eversense XL glucose monitor
Senseonics (NYSE:SENS) said yesterday that it won CE Mark approval in the European Union for its Eversense XL continuous glucose monitor. The Eversense XL includes a glucose sensor designed to be implanted for 180 days and a removable smart transmitter that links with a mobile app for real-time glucose monitoring. Germantown, Md.-based Senseonics touts the sensor […]
Senseonics inks artificial pancreas deal with Roche, TypeZero Technologies
Senseonics (NYSE:SENS) said today that it inked a collaboration with TypeZero Technologies and Roche (OTC:RHHBY) Diabetes Care to develop an automated insulin delivery system. The deal is part of an NIH-funded effort to test artificial pancreas systems. The trial is slated to integrate Senseonic’s Eversense glucose monitor, TypeZero’s inControl AP algorithms and Roche’s Accu-Chek Insight insulin pump. […]
Senseonics prices $41m underwritten offering for Eversense CGM
Senseonics (NYSE:SENS) said today that it priced an underwritten offering of 29 million shares of common stock at $1.41 apiece to a group of institutional investors. Roche (PINK:RHHBY) agreed to purchase 21 million shares and New Enterprise Associates agreed to purchase 7 million shares in the offering, according to the Germantown, Md.-based company. Senseonics said […]